You're receiving this email because of your subscription to CancerMPact® to receive our
complimentary Oncology E-Newsletter, Leonardo's Notebook. We invite you to review the latest
issue and download it directly from the CancerMPact website:
http://www.cancermpact.com
This edition of Leonardo's Notebook marks our fourth year bringing to our clients analysis of the
key events in oncology. In this issue devoted to the joint European Cancer Organization (ECCO)
– European Society of Molecular Oncology (ESMO) conference, which took place in September
2009 in Berlin Germany, we are reporting on three important developments. There were several
high-impact data that were released at the ECCO-ESMO Conference, which MattsonJack
DaVinci feels are worthy of comment:
•
•
•
Vectibix: Moving from Fourth-Line to Frontline
Prolia Rising
SOLTI-0701: Despite the Excitement, More of the Same
The first story relates to the first prospective analyses of KRAS in colorectal cancer, conducted as
part of the pivotal studies of Vectibix  (panitumumab, Amgen) in combination with chemotherapy.
The second story discusses the pivotal program for Prolia  (denosumab, Amgen), an emerging
new therapy for the prevention and treatment of bone complications (skeletal-related events) due
to bone metastases. We also noted the excitement at this conference for the Phase II trial
examining Nexavar (sorafenib, Bayer Schering) in combination with Xeloda (capecitabine,
Roche) for the treatment of breast cancer, a study which helps better define where multitargeted
kinase inhibitors might find use in this disease.
This e-newsletter is intended to provide commercial organizations involved in the development
and marketing of new cancer therapeutics with topical articles and features relating to oncology.
Each edition will include news and comment about issues that may impact an organization's
development and commercialization strategies, such as government policies and initiatives,
pricing and reimbursement, and reports about the latest research on specific cancers by
competitors. Additional information about forthcoming oncology meetings will also be included,
together with features about MattsonJack DaVinci's Oncology products and services:
http://www.mattsonjack.com/davincioncologycomp.asp
For more information on Leonardo's Notebook, send your contact information to:
Claudia.Martinez-Triggs@kantarhealth.com.
MattsonJack DaVinci
Dr. Richard Wagner, Senior Director
richard.wagner@kantarhealth.com
Ian Hicks, Senior Vice President
Ian.hicks@kantarhealth.com
*************************************************************************************
If you are not receiving this information directly and would like Opt In the distribution list, or to Opt
Out from receiving future issues of Leonardo's Notebook, e-mail us: info@kantarhealth.com
mailto:info@kantarhealth.com